XCUR (Exicure) Short Interest


XCUR Exicure Inc XCUR
30 GF Score
Price $2.66
GF Value $0.54
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Exicure Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XCUR vs GRTX, AEON, ANEB: Short Interest Comparison

For the Biotechnology subindustry, Exicure's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exicure Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exicure's Short Interest distribution charts can be found below:

* The bar in red indicates where Exicure's Short Interest falls into.


XCUR
30GF Score
Exicure Inc XCUR
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Exicure (XCUR) Overvalued in 2026?

Based on GuruFocus' analysis, Exicure stock appears to be overvalued. The current stock price of $2.66 is trading 391.7% above its estimated GF Value™ of $0.54. GuruFocus considers Exicure to be Significantly Overvalued.

Key valuation signals for XCUR:

  • Short Interest:
  • GF Value™: $0.54 vs. price of $2.66 (391.7% above fair value)
  • GF Score™: 30/100 with 3 warning signs

No single metric tells the full story. See the XCUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Exicure Business Description

Other Exchanges 2H0:Germany
Address 400 Seaport Court, Suite 102, Redwood City, CA, USA, 94063
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
30GF Score

Get the complete analysis for XCUR

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.66
Price
$0.54
GF Value